Phase II trial of capecitabine in recurrent squamous cell carcinoma of the cervix

Gynecologic Oncology

Volumn 97, Issue 3, 2005, Pages 840-844

  Jenkins, Alfred D ^a   Ramondetta, Lois M ^a   Sun, Charlotte ^a   Johnston, Taren ^a   Wolf, Judith K ^a   Bodurka, Diane C ^a   Brown, Jubilee ^a   Atkinson, Edward N ^a   Levenback, Charles ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Capecitabine; Metastatic cervical cancer; Recurrent squamous cell carcinoma

Indexed keywords

CAPECITABINE; FLUOROURACIL;

ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DATA ANALYSIS; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG INFUSION; DRUG RESPONSE; FEMALE; HUMAN; PHASE 2 CLINICAL TRIAL; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RATING SCALE; RECURRENT DISEASE; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, SQUAMOUS CELL; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; UTERINE CERVICAL NEOPLASMS;

EID: 20444438255     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.02.029     Document Type: Article

References (32)

1. SEER cancer statistics review. [online, 2003]. [cited, 2001] Available from: URL: http://www.Seer.cancer.gov.
2. E.L. Franco, N.F. Schlecht, and D. Saslow The epidemiology of cervical cancer Cancer 9 2003 348 359
3. T.W. Report Report of the Task Force of the Department of Health and Welfare of Canada. Cervical cancer screening programs. The Walton Report Can. Med. Assoc. J. 127 1982 581
4. G.D. Malkasian Jr., D.G. Decker, and E.O. Jorgensen Chemotherapy of carcinoma of the cervix Gynecol. Oncol. 5 1976 109 120
5. J.T. Thigpen Single agent chemotherapy in carcinoma of the cervix E.A. Surwitt D.S. Alberts Cervix Cancer 1987 Martinus Hijhoff Boston 119 136
6. M. Morris, K.R. Brader, C. Levenback, and T.W. Burke Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix J. Clin. Oncol. 16 1998 1094 1098
7. W.P. McGuire, J.A. Blessing, D. Moore, S.S. Lentz, and G. Photopulos Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study J. Clin. Oncol. 14 1996 792 795
8. C.F. Vershraegen, T. Levey, A.P. Kudelka, E. Llerena, K. Ende, and R. Freedman Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix J. Clin. Oncol. 15 1997 625 631
9. J.T. Thigpen, H. Shingleton, H. Homesley, L. Lagasse, and J. Blessing Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix. A phase II study of the Gynecologic Oncology Group Cancer 48 1981 899 903
10. G. Zanetta, W. Torri, and L. Bocciolone Factors predicting response to chemotherapy and survival in patients with metastatic or recurrent Squamous cell cervical carcinoma. A multivariate analysis Gynecol. Oncol. 58 1995 58 63
11. W.J. Hoskins, C. Perez, and R.C. Young Gynecologic tumors V.T. Devita Jr. S. Hellman S.A. Roasenberg Cancer: Principles and Practice of Oncology 3rd ed. 1989 J.B. Lippincott Company Philadelphia
12. P. Bonomi, and E. Yordan Chemotherapy of cervical carcinoma G. Deppe Chemotherapy of Gynecologic Cancer 2nd ed. 1990 Alan R. Liss, Inc New York
13. D.H. Moore, J.A. Blessing, R.P. McQuellon, and H.T. Thaler Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study J. Clin. Oncol. 22 2004 3113 3119
14. G.A. Omura, J.A. Blessing, L. Vaccarello, and M.L. Berman Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study J. Clin. Oncol. 15 1997 165 171
15. C.A. Papadimitriou, K. Sarris, L.A. Moulopoulos, and G. Fountzilas Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix J. Clin. Oncol. 17 1999 761 766
16. P.G. Rose, J.A. Blessing, D.M. Gershenson, and R. McGehee Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study J. Clin. Oncol. 17 1999 2676 2680
17. S. Pignata, G. Silvestro, E. Ferrari, and L. Selvaggi Phase II study of cisplatin and vinorelbine as first-line chemotherapy in patients with carcinoma of the uterine cervix J. Clin. Oncol. 17 1999 756 760
18. H.J. Long, E.C. Grendys, J. Brenda, and B.L. Monk A randomized phase III study of cisplatin versus cisplatin plus topotecan versus MVAC in stage IVB, recurrent or persistent carcinoma of the cervix Gynecol. Oncol. 84 3 2002 479 [Abstract]
19. K.Y. Look, J.A. Blessing, D.G. Gallup, and S.S. Lentz A Phase II trial of 5-fuorouracil and high dose leucovorin in patients with recurrent squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study Am. J. Clin. Oncol. 19 1996 439 441
20. J. Kaern, C. Trope, K. Sundfoer, and G.B. Kristensen Cisplatin/5- fluorouracil treatment of recurrent cervical carcinoma: a phase II study with long term follow-up Gynecol. Oncol. 60 1996 387 392
21. M. Morris, P.J. Eifel, J. Lu, P.W. Grigsby, C. Levenback, and R.D. Stevens Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer N. Engl. J. Med. 340 1999 1137 1143
22. M. Miwa, M. Ura, N. Nishida, T. Sawada, K. Ishikawa, and N. Mori Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue Eur. J. Cancer 34 1998 1274 1281
23. T. Ishikawa, M. Utoh, N. Sawada, M. Nishida, Y. Fukase, and F. Sekiguchi Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts Biochem. Pharmacol. 1998 1091 1097
24. Roche Laboratories. Xeloda (capecitabine) prescribing information. [online, 1999]. [cited 1999]. Available from: URL: http://www.xeloda.com/xeloda/ XELODA_PI.html.
25. G. Liu, E. Franssen, M. Fitch, and E. Warner Patient preference for oral versus intravenous palliative chemotherapy J. Clin. Oncol. 15 1997 110 115
26. M.J. MacKean, A.S. Plantins, C. Twelves, J. Schellens, D. Allman, and B. Osterwalder Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer J. Clin. Oncol. 16 1998 2977 2985
27. J.L. Blum, S.E. Jones, A.U. Buzdar, P.M. LoRusso, I. Kuter, and C. Vogel Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer J. Clin. Oncol. 17 1999 485 493
28. T.H. Cartwright, A. Cohn, J.A. Varkey, Y.-M. Chen, T.P. Szatrowski, and J.V. Cox Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer J. Clin. Oncol. 20 2002 160 164
29. B.J. Monk Abstract Gynecol. Oncol. 92 1 2004 473 [SGO #177]
30. P.M. Hoff, R. Pazdur, Y. Lassere, S. Carter, D. Samid, and D. Poloto Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma J. Clin. Oncol. 22 2004 2078 2081
31. M. Toi, H. Brando, S. Horiguchi, M. Takada, A. Kataoka, and T. Ueno Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer Br. J. Cancer 90 2004 2338 2343
32. J. Ciccolini, A. Evrard, and P. Cuq Thymidine phosphorylase and fluoropyrimidines efficacy: a Jekyl and Hyde story Curr. Med. Chem. Anti-Cancer Agents 4 2004 71 81